Immune Engineering & Cancer Control

This field covers efforts to keep the immune system working well into old age, including reducing the chronic, low-grade inflammation associated with aging. It also covers work to prevent or control cancer, which becomes far more common as immune function weakens.

A weakened, poorly regulated immune system is linked to many age-related diseases, including cancer. Keeping the immune system functional is likely necessary for other longevity approaches to succeed, because their benefits could otherwise be undermined by immune decline.

That would support the broader goal of Longevity Escape Velocity: reaching a point where advances across multiple medical fields extend healthy lifespan faster than time passes.

• Immune rejuvenation: Research aimed at restoring or maintaining immune function with age.
• Inflammation control: Approaches targeting the chronic, low-grade inflammation associated with aging.
• Cancer prevention: Prevention and early-detection research tied to immune function.
• Immune-based therapies: Treatments that use the immune system against aging-related disease.

• General cancer-treatment news unrelated to aging or immune function.
• Isolated laboratory findings with no discussion of relevance to aging.
• Supplement or lifestyle claims without described clinical evidence.

• Complexity: The immune system is interconnected, which makes targeted intervention difficult.
• Balance: Reducing inflammation must be weighed against maintaining immune strength.
• Long-term safety: Durable safety data for immune-modulating therapies remain limited.
• Individual variation: The immune system ages differently from person to person.

Highest score among the biology fields and a large contribution, because this field has the most actually-deployed technology: checkpoint inhibitors and CAR-T are standard of care, not promises. 2006 pre-dates both. Cancer and inflammaging together account for an enormous share of the mortality and morbidity that must be removed before any other intervention can show a healthspan signal, so progress here is a precondition for measuring progress anywhere else. Thymic regeneration and in-vivo CAR are credible near-term unlocks.

This readiness score is a published model input, not a measurement or clinical forecast. It summarizes the field under the assumptions documented in the model and does not predict that any specific intervention will succeed. It should be treated as an evolving assessment, not a guaranteed roadmap.